One source says the company is exploring whether to enter the drug purchasing market.
Biotech stocks jump this week on news of Gilead's $12 billion acquisition of Kite Pharma Inc.
Drug stocks may be hurt by slashed sales and earnings as prices soften
Major biotech funds are struggling after a series of high-profile drug pricing scandals, but that hasn't stopped the flow of junior biotech winners. (CNAT)
Novartis licensed ECF843 eye drops outside Europe from Lubris LLC.
Ibrance got FDA approval and an expanded Indication to treat metastatic breast cancer.
Novartis has secured approval from the European Commission for its lung cancer drug combo.
CTL019 marks Novartis’ first regulatory submission for a CAR-T therapy.
Ocrevus is expected to be a blockbuster drug for Roche, as the company faces generics challenge for its older, established cancer drugs
Novartis licensed 2 of its drugs to Puretech Health in exchange an equity stake and milestone pay.